Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.280
-0.180 (-5.20%)
At close: Jun 2, 2026, 4:00 PM EDT
3.261
-0.019 (-0.59%)
After-hours: Jun 2, 2026, 7:58 PM EDT
Ironwood Pharmaceuticals Employees
Ironwood Pharmaceuticals had 100 employees as of December 31, 2025. The number of employees decreased by 153 or -60.47% compared to the previous year.
Employees
100
Change (1Y)
-153
Growth (1Y)
-60.47%
Revenue / Employee
$3,615,140
Profits / Employee
$1,021,760
Market Cap
539.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 100 | -153 | -60.47% |
| Dec 31, 2024 | 253 | -14 | -5.24% |
| Dec 31, 2023 | 267 | 48 | 21.92% |
| Dec 31, 2022 | 219 | 0 | - |
| Dec 31, 2021 | 219 | -13 | -5.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Pacira BioSciences | 829 |
| Kamada | 462 |
| Evolus | 350 |
| Esperion Therapeutics | 294 |
IRWD News
- 5 days ago - Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 6 days ago - Ironwood says FDA approves use of Linzess in pediatric patients two and older - TheFly
- 6 days ago - FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC) - Business Wire
- 26 days ago - Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 26 days ago - Ironwood Pharmaceuticals Earnings release: Q1 2026 - Filings
- 26 days ago - Ironwood Pharmaceuticals Slides: Q1 2026 - Filings
- 26 days ago - Ironwood Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 26 days ago - Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance - Business Wire